Exciting news from FoRx today, with successful dosing of the first patient in a first-in-human clinical study of FORX-428. An initial data readout from the trial is expected by mid-2026. FORX-428 is a novel PARG inhibitor designed to target and disrupt the DNA Damage Response (DDR) in advanced solid tumors. The approval of PARP inhibitors more than 10 years ago transformed cancer treatment, and by pursuing a next-generation DDR target, called PARG, FoRx is seeking to further advance this strategy. “FoRx is built on the disruptive potential of PARG inhibition as a therapeutic strategy. FORX-428 has demonstrated exquisite anti-tumor efficacy in multiple preclinical in vivo tumor models, suggesting best-in-class potential,” says @Tarig Bashir, CEO of FoRx Therapeutics. “The entry of FORX-428 into clinical development is a major milestone in our mission to redefine cancer therapy by offering better treatment options for patients.” Click here for the full press release [https://lnkd.in/ezfBX-Bj] #Biotech #Cancer #ClinicalDevelopment #DNADamageResponse #Healthcare #Oncology
FoRx Therapeutics
Biotechnologieforschung
Basel, Basel 5.863 Follower:innen
FoRx Therapeutics is developing therapeutics that exploit the presence of DNA replication stress in human cancers
Info
FoRx Therapeutics is a recently incorporated privately-held company based in Basel, Switzerland. It is backed by a syndicate of investors that include the Novartis Venture Fund, Pfizer Ventures, M Ventures, Omega Funds and LSP Venture Capital. FoRx Therapeutics focuses on drugging key molecular targets involved in the DNA Replication Stress, as a new approach in the development of targeted anticancer drugs.
- Website
-
https://www.FoRxTx.com
Externer Link zu FoRx Therapeutics
- Branche
- Biotechnologieforschung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Basel, Basel
- Art
- Privatunternehmen
- Gegründet
- 2019
Orte
-
Primär
Wegbeschreibung
Basel, Basel 4056, CH
Beschäftigte von FoRx Therapeutics
-
Frank Zenke
CSO at FoRx Therapeutics
-
Michael Kauffman
Drug Developer, Board Member, Physician Scientist
-
Nicolas Bocquet
Director-Head of Protein Sciences (Small molecules | Biochemistry | Biophysics | Structural Biology) chez FoRx Therapeutics
-
Nadiya Ishnazarova
Principal at M Ventures, Biotechnology Investments | PhD Biochemistry and Genetics
Updates
-
Do not miss today's presentation by my colleague Ulrich Luecking, VP, Head of Chemistry at FoRx Therapeutics: "Sulfoximines in Medicinal Chemistry: Unlocking Novel Opportunities in Drug Design" https://lnkd.in/dN7BcR5S
-
FoRx Therapeutics hat dies direkt geteilt
Join us at BIO-Europe Spring as Tarig Bashir, CEO at FoRx Therapeutics, takes the stage to showcase their latest innovations in Oncology. Don’t miss this opportunity to hear firsthand how they are shaping the future of biotech! 🤝 Register now and start engaging: http://spr.ly/6047LLk2x 📅 BIO-Europe Spring | March 17–19, 2025 📍 Milan, Italy
-
🧬 We’re thrilled to welcome Serena Bologna, PhD, Principal Scientist at FoRx Therapeutics, as a guest speaker at Champions’ Annual European Translational Oncology Symposium on March 13, 2025, in Basel, Switzerland! 🔬With over 15 years of expertise in cancer biology and DNA damage repair pathways, Dr. Bologna has contributed significantly to the discovery of novel drug targets and predictive biomarkers. Her talk, "FORX-428: A Novel, Potent PARG Inhibitor Demonstrating Strong Anti-Tumor Activity in Preclinical Cancer Models," will explore the exciting potential of PARG inhibition in cancer treatment. 📍Don’t miss this must-attend session : https://hubs.li/Q038ZV280 #OncologyInnovation #CancerResearch #TranslationalOncology2025 #CancerTherapies #ImmunoOncology #PreclinicalResearch #OncologySymposium #ADC #IO #Basel #switzerland #EU #colorectalcancer Swiss Biotech Association, BioAlps - Swiss Health Valley, Biopôle Lausanne
-
-
FoRx Therapeutics hat dies direkt geteilt
Director-Head of Protein Sciences (Small molecules | Biochemistry | Biophysics | Structural Biology) chez FoRx Therapeutics
Looking forward to participating to the 2nd Biophysics for drug discovery summit. https://ter.li/wcv74r
-
-
We are excited to announce the appointment of Jens Würthner as Chief Medical Officer at FoRx Therapeutics! Jens has more than 20 years of experience in clinical development and successfully led clinical programs in oncology and other therapeutic areas at pharma and biotech companies. His long-standing and profound expertise will be key in leading and advancing FoRx Therapeutics’ PARG inhibitor FORX-428 into and through the clinic. Welcome to the team, Jens, we are thrilled to have you on board and very much look forward to working with you! https://lnkd.in/eMH_SaCd
-
-
FoRx Therapeutics hat dies direkt geteilt
FoRx Therapeutics is a preclinical-stage company dedicated to the discovery and development of innovative, next-generation oncology drugs that target DNA Damage Response (DDR) pathways in cancer. Our lead program is a potent and selective PARG inhibitor (FORX-428) with strong evidence for best-in-class potential, which was recently declared as Development Candidate and is currently progressing to IND. Meet FoRx Therapeutics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dZGJTXwa #LifeSciences #BiotechInEuropeForum #EuropeanBiotech #PharmaIndustry #BiotechConference #HealthTech #InvestmentForum #Biopharma #MedTech #BioPharma #DigitalHealth #InvestmentOpportunities #BiotechStartups #BiotechInvestment #LifeSciencesInnovation
-